Italia markets open in 7 hours 57 minutes

Telesis Bio, Inc. (TBIO)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
0,3213+0,0017 (+0,53%)
Alla chiusura: 04:00PM EDT
0,3303 +0,01 (+2,80%)
Dopo ore: 05:25PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,3196
Aperto0,3010
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,3010 - 0,3500
Intervallo di 52 settimane0,3000 - 3,0100
Volume127.696
Media Volume767.811
Capitalizzazione9,672M
Beta (5 anni mensile)1,92
Rapporto PE (ttm)N/D
EPS (ttm)-1,6400
Prossima data utili10 mag 2024 - 14 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

    New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology WorkstationSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep kit for Whole Genome Sequencing on the BioXp 3250 and BioXp 9600 systems. This NGS libr

  • GlobeNewswire

    Telesis Bio Appoints William J. Kullback Chief Financial Officer

    SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. “Bill’s deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to

  • GlobeNewswire

    Telesis Bio Reports Second Quarter 2023 Financial Results

    -- Total revenue of $8.7M in 2QFY23 - increased by 53% year over yearSAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. “We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding gross margins and reducing operating expenses. In addition, we raised capital during the qu